← Back to Clinical Trials
Recruiting NCT05646745

NCT05646745 Autologous Transobturator Fascia Lata Sling in Treatment of Female Stress Urinary Incontinence

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05646745
Status Recruiting
Phase
Sponsor Al-Azhar University
Condition Stress Urinary Incontinence
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2022-01-01
Primary Completion 2025-10-01

Eligibility & Interventions

Sex Female only
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Autologous Transobturator Fascia Lata Sling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2022-01-01 with a primary completion date of 2025-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the outcome of autologous transobturator fascia lata sling for treatment of female stress urinary incontinence at Al-Azhar university hospitals.

Eligibility Criteria

Inclusion Criteria: * Women with genuine stress urinary incontinence. * Mixed urinary incontinence with predominant stress element. * Refractory cases to conservative therapy or patients who are not willing to consider (further) conservative treatment. Exclusion Criteria: * Mixed incontinence with predominant Urge urinary incontinence. * Associated local abnormalities that may affect surgery outcomes (e.g. complete procidentia). * Recent or active urinary tract infection. * Recent pelvic surgery. * Neurogenic lower urinary tract dysfunction. * Previous surgery for stress urinary incontinence. * Pregnancy * Less than 12 months post-partum. * Other gynaecologic pathologies affecting bladder functions ( eg, large fibroids, ovarian cysts) * Genito-urinary malignancy. * Current chemo or radiation therapy.

Contact & Investigator

Central Contact

Mohamed F Salman, MD

✉ Prof_mohamed_fawzy@yahoo.com

📞 00201111788996

Frequently Asked Questions

Who can join the NCT05646745 clinical trial?

This trial is open to female participants only, studying Stress Urinary Incontinence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05646745 currently recruiting?

Yes, NCT05646745 is actively recruiting participants. Contact the research team at Prof_mohamed_fawzy@yahoo.com for enrollment information.

Where is the NCT05646745 trial being conducted?

This trial is being conducted at Cairo, Egypt, Cairo, Egypt.

Who is sponsoring the NCT05646745 clinical trial?

NCT05646745 is sponsored by Al-Azhar University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology